Cleveland Clinic is teaming up with venture firm Khosla Ventures to give startups real clinical testbeds, speed up validation of bold health tech ideas, and scale solutions in AI, therapeutics, diagnostics, and care delivery for populations in need.
Glimpse:
The Cleveland Clinic has entered into a strategic collaboration with Khosla Ventures aimed at accelerating early-stage health technologies from proof-of-concept to impact. Under this agreement, Khosla-backed portfolio companies will get opportunities to test and validate their technologies within Cleveland Clinic’s clinical settings. At the same time, the Clinic gains early access to emerging innovations in AI, personalized diagnostics, value-based care, and new care delivery models. Joint incubation of new companies is also being explored, along with commercial relationships already forming. Priority areas include oncology, neurology, cardiology, AI-driven diagnostics, and care delivery models that extend beyond hospital walls into home and community care.
Imagine a bridge between the daring ideas of Silicon Valley and the clinical rigor of a world-class medical system that’s exactly what Cleveland Clinic and Khosla Ventures are building.
The new strategic collaboration is designed to let health tech startups accelerate through the usual slow phases of validation. Startups backed by Khosla Ventures will gain access to Cleveland Clinic’s clinicians, real workflows, patient-data environments, and clinical validation channels. That means better feedback early, faster iteration, and more opportunities to scale innovations that are truly fit for hospitals, clinics, and patients.
From the Cleveland side, there’s a lot to gain too. Khosla’s portfolio gives a window into promising new diagnostics, digital health tools, generative AI, and therapeutic ideas letting the Clinic stay at the cutting edge. It’s not just watching from the sidelines: Cleveland will be part of testing, refining, and helping commercialise these technologies.
Some concrete features of the collaboration include:
Clinical validation across specialties like oncology, cardiology, neurology, and musculoskeletal care.
Building new care delivery models perhaps more home-based or outpatient-oriented, or global second-opinion services.
Joint incubation: in some cases, forming new companies together, where Khosla handles technical build and recruiting, and Cleveland Clinic provides clinical testbeds and mentorship.
Value-based care models for underserved populations (including those under Medicare/Medicaid/double-eligible) the idea being that innovation isn’t only for high-margin care, but care that needs to be cost-sensitive and outcome-driven.
Certainly, this won’t be without challenges. Validating new tech in healthcare is always risky: regulatory approval, safety, efficacy, bias, integration into messy existing clinical workflows, reimbursement, and making sure innovations are accessible and equitable. But both partners seem aligned on the belief that accelerating validation and deployment yields better patient outcomes, and that some of the biggest wins will come where technology meets real clinical need.
“Khosla Ventures invests in early, bold, and impactful ideas that help people get healthy, stay healthy, and live longer This relationship with Cleveland Clinic gives our companies an advantage to validate and scale their innovations.”
By
HB Team
Related News
